388 related articles for article (PubMed ID: 16952495)
1. Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations.
Nakajima M; Fukami T; Yamanaka H; Higashi E; Sakai H; Yoshida R; Kwon JT; McLeod HL; Yokoi T
Clin Pharmacol Ther; 2006 Sep; 80(3):282-97. PubMed ID: 16952495
[TBL] [Abstract][Full Text] [Related]
2. Nicotine metabolism and CYP2A6 allele frequencies in Koreans.
Kwon JT; Nakajima M; Chai S; Yom YK; Kim HK; Yamazaki H; Sohn DR; Yamamoto T; Kuroiwa Y; Yokoi T
Pharmacogenetics; 2001 Jun; 11(4):317-23. PubMed ID: 11434509
[TBL] [Abstract][Full Text] [Related]
3. Characterization of novel CYP2A6 polymorphic alleles (CYP2A6*18 and CYP2A6*19) that affect enzymatic activity.
Fukami T; Nakajima M; Higashi E; Yamanaka H; Sakai H; McLeod HL; Yokoi T
Drug Metab Dispos; 2005 Aug; 33(8):1202-10. PubMed ID: 15900015
[TBL] [Abstract][Full Text] [Related]
4. CYP2A7 polymorphic alleles confound the genotyping of CYP2A6*4A allele.
Fukami T; Nakajima M; Sakai H; McLeod HL; Yokoi T
Pharmacogenomics J; 2006; 6(6):401-12. PubMed ID: 16636685
[TBL] [Abstract][Full Text] [Related]
5. Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans.
Nakajima M; Kwon JT; Tanaka N; Zenta T; Yamamoto Y; Yamamoto H; Yamazaki H; Yamamoto T; Kuroiwa Y; Yokoi T
Clin Pharmacol Ther; 2001 Jan; 69(1):72-8. PubMed ID: 11180041
[TBL] [Abstract][Full Text] [Related]
6. A novel polymorphism of human CYP2A6 gene CYP2A6*17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo.
Fukami T; Nakajima M; Yoshida R; Tsuchiya Y; Fujiki Y; Katoh M; McLeod HL; Yokoi T
Clin Pharmacol Ther; 2004 Dec; 76(6):519-27. PubMed ID: 15592323
[TBL] [Abstract][Full Text] [Related]
7. CYP2A6 genotype and the metabolism and disposition kinetics of nicotine.
Benowitz NL; Swan GE; Jacob P; Lessov-Schlaggar CN; Tyndale RF
Clin Pharmacol Ther; 2006 Nov; 80(5):457-67. PubMed ID: 17112802
[TBL] [Abstract][Full Text] [Related]
8. A novel duplication type of CYP2A6 gene in African-American population.
Fukami T; Nakajima M; Yamanaka H; Fukushima Y; McLeod HL; Yokoi T
Drug Metab Dispos; 2007 Apr; 35(4):515-20. PubMed ID: 17267622
[TBL] [Abstract][Full Text] [Related]
9. Interindividual variability in nicotine metabolism: C-oxidation and glucuronidation.
Nakajima M; Yokoi T
Drug Metab Pharmacokinet; 2005 Aug; 20(4):227-35. PubMed ID: 16141602
[TBL] [Abstract][Full Text] [Related]
10. Interindividual differences in nicotine metabolism and genetic polymorphisms of human CYP2A6.
Nakajima M; Kuroiwa Y; Yokoi T
Drug Metab Rev; 2002 Nov; 34(4):865-77. PubMed ID: 12487152
[TBL] [Abstract][Full Text] [Related]
11. A novel CYP2A6*20 allele found in African-American population produces a truncated protein lacking enzymatic activity.
Fukami T; Nakajima M; Higashi E; Yamanaka H; McLeod HL; Yokoi T
Biochem Pharmacol; 2005 Sep; 70(5):801-8. PubMed ID: 15993850
[TBL] [Abstract][Full Text] [Related]
12. Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism.
Yoshida R; Nakajima M; Watanabe Y; Kwon JT; Yokoi T
Br J Clin Pharmacol; 2002 Nov; 54(5):511-7. PubMed ID: 12445030
[TBL] [Abstract][Full Text] [Related]
13. Ethnic variation in CYP2A6*7, CYP2A6*8 and CYP2A6*10 as assessed with a novel haplotyping method.
Mwenifumbo JC; Myers MG; Wall TL; Lin SK; Sellers EM; Tyndale RF
Pharmacogenet Genomics; 2005 Mar; 15(3):189-92. PubMed ID: 15861044
[TBL] [Abstract][Full Text] [Related]
14. CYP2A6 genotype, phenotype, and the use of nicotine metabolites as biomarkers during ad libitum smoking.
Malaiyandi V; Goodz SD; Sellers EM; Tyndale RF
Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1812-9. PubMed ID: 17035386
[TBL] [Abstract][Full Text] [Related]
15. The contribution of common CYP2A6 alleles to variation in nicotine metabolism among European-Americans.
Bloom J; Hinrichs AL; Wang JC; von Weymarn LB; Kharasch ED; Bierut LJ; Goate A; Murphy SE
Pharmacogenet Genomics; 2011 Jul; 21(7):403-16. PubMed ID: 21597399
[TBL] [Abstract][Full Text] [Related]
16. Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro.
Yoshida R; Nakajima M; Nishimura K; Tokudome S; Kwon JT; Yokoi T
Clin Pharmacol Ther; 2003 Jul; 74(1):69-76. PubMed ID: 12844137
[TBL] [Abstract][Full Text] [Related]
17. Differences between Spaniards and Ecuadorians in CYP2A6 allele frequencies: comparison with other populations.
Soriano A; Vicente J; Carcas C; Gonzalez-Andrade F; Arenaz I; Martinez-Jarreta B; Fanlo A; Mayayo E; Sinués B
Fundam Clin Pharmacol; 2011 Oct; 25(5):627-32. PubMed ID: 21410749
[TBL] [Abstract][Full Text] [Related]
18. A novel CYP2A6 allele (CYP2A6*35) resulting in an amino-acid substitution (Asn438Tyr) is associated with lower CYP2A6 activity in vivo.
Al Koudsi N; Ahluwalia JS; Lin SK; Sellers EM; Tyndale RF
Pharmacogenomics J; 2009 Aug; 9(4):274-82. PubMed ID: 19365400
[TBL] [Abstract][Full Text] [Related]
19. Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians.
Schoedel KA; Hoffmann EB; Rao Y; Sellers EM; Tyndale RF
Pharmacogenetics; 2004 Sep; 14(9):615-26. PubMed ID: 15475735
[TBL] [Abstract][Full Text] [Related]
20. CYP2A6 and CYP2E1 polymorphisms in a Brazilian population living in Rio de Janeiro.
Rossini A; Lima SS; Rapozo DC; Faria M; Albano RM; Pinto LF
Braz J Med Biol Res; 2006 Feb; 39(2):195-201. PubMed ID: 16470306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
